Canada - English - Health Canada

teva canada limited - cefaclor - capsule - 250mg - cefaclor 250mg - second generation cephalosporins

Canada - English - Health Canada

teva canada limited - cefaclor - capsule - 500mg - cefaclor 500mg - second generation cephalosporins

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes   lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes   pharyngitis and tonsillitis , caused by streptococcus pyogenes   note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphy

United States - English - NLM (National Library of Medicine)

alvogen, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg

United States - English - NLM (National Library of Medicine)

avadel pharmaceuticals (usa), inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 16 december 1997: keflor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis: community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tract infections, including cystisis; skin and skin structure infections. note 1. penicillin in the usual drug of choice in the treatment and prevention of streptoccocal infections, including the prophylaxis of rheumatic fever. keflor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of keflor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - keflor is indicated for the treatment of the following types of infections caused by or likely to be caused susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflor appears to be effective as phenoxymethul penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organisms to cefaclor.